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1939–2014Stephen F. HeinemannStarting in the late 1960s and early 1970s,
a group of aspiring young scientists gath-
ered at the Salk Institute for Biological
Studies in La Jolla, California. This group
of trainees and junior faculty included
Steve Heinemann, Rudolf Jaenisch, Inder
Verma, Tony Hunter, the late Wylie Vale,
and, soon thereafter, Ron Evans. In the
years to come, this erstwhile group of
young mavericks went on to define sci-
ence not only at the Salk but, in some
sense, for the entire world. In neurosci-
ence, the defining force was Stephen
F. Heinemann, who passed away on
August 6, 2014, of kidney failure. For
several years, Steve was elected the
head of the Faculty at the Salk, and
his beloved and yet straightforward,
honest character served him well in
bringing together diverse personalities,
approaches, and interests.
Steve was best known for his science.
He and his colleagues changed the way
we view neurotransmitter receptors in
the brain, thus influencing the future study
of learning, memory, and disease. He,
more than anyone else, taught us the
power of cloning these receptors, charac-
terizing their properties, and determining
how mutations influence their function.
Prior to Steve’s work, we knew that excit-
atory neurotransmitters mediated these
processes via synaptic transmission, but
their receptors remained contentious,
usually named for the ligand with the high-
est affinity. Steve and his colleagues,
particularly Jim Patrick, and also Jim
Boulter, Michael Hollmann, and others,
changed all this—cloning various sub-
units of the neuronal receptors for both
acetylcholine (nicotine) and glutamate,
the two major excitatory transmitters.
Steve and his group went on to sort out
how the various subunits and their con-
stituent amino acids accounted for many
of the well-known properties of these
neurotransmitter receptors. This toolbox
allowed the field to study in depth the
molecular underpinnings of normal pro-
cesses such as learning and memory,
as well as many neurological diseases.
These maladies range from myastheniagravis to traumatic brain injury to Hunting-
ton’s disease to Alzheimer’s disease. In
recent years, it has become clear that
aberrant function of these receptors also
contributes to neuropsychiatric disorders.
Moreover, his discovery of these recep-
tors gave pharmaceutical companies
new targets to explore in order to treat
these diseases. Upon his death, the Salk
Institute wrote, ‘‘Groundbreaking findings
from his laboratory supported the idea
that many diseases of the brain result
from deficits in communication between
nerve cells, and he waswidely considered
one of the world’s most accomplished
neuroscientists.’’
Born in 1939 to Robert B. Heinemann
and Christel Fuchs, Steve lived in
Cambridge, Massachusetts during his
early years and attended Buckingham
Browne & Nichols secondary school.
This must have been a very exciting time
in Cambridge. Rumor had it that Steve’s
first chemistry set came from his uncle,
Klaus Fuchs, a theoretical physicist who
had worked on the Manhattan project
under Hans Bethe during World War II
but later confessed to being a communist
spy. Steve met his wife of 54 years, Ann
Reischauer Heinemann, in Cambridge,
and her side of the family was no less bril-
liant and interesting than his. Ann’s father,
Edwin Reischauer, a renowned Harvard
professor of East Asian studies, servedCell 15as US ambassador to Japan in the
1960s. Reischauer was effective in large
measure because his second wife, Haru
Matsukata, granddaughter of a prince
and former prime minister of Japan, was
a revered symbol of Japanese culture
and mores. She was introduced to Edwin
Reischauer by none other than the
novelist James Michener, and together
the Reischauers eased tensions between
Japan and the US after World War II.
And Ann Heinemann, like her father Edwin
and her stepmother Haru, did not fall far
from the tree—brilliant in her own right,
with tremendous insight into human char-
acter and concern for the welfare of hu-
mankind. Ann was very influential on
Steve and his unfaltering values for hu-
manity, fairness, and justice.
Steve earned his undergraduate degree
from Caltech in 1962 and a PhD in
biochemistry under advisor Matt Mesel-
son at Harvard in 1967 and then per-
formed postdoctoral work at MIT and
Stanford. During this period, Steve was
also known for his prowess as a baseball
pitcher at Caltech (of all places). With his
wry sense of wit, Steve recounted that
the Caltech coach once came to the
mound to take him out of the game after
getting behind 12 to 0 in the third inning
but only to preserve his arm so he could
start the second game of the double-
header to be played later that same
afternoon!
After joining the Salk Institute in 1970,
at the behest of nonresident fellow
and advisor Stephen Kuffler from Har-
vard, Heinemann founded the Molecular
Neurobiology Laboratory, ‘‘a program
that by the late 1980s was ranked number
one in the world,’’ according to Salk Insti-
tute sources. During those early years,
Steve worked on nerve-muscle prepara-
tions and snake-derived nicotinic toxins
with Dave Schubert, John Henry Stein-
bach, Jim Patrick, and others. Unex-
pectedly, while making antibodies to
acetylcholine receptors isolated from the
eel electric organ, Jim Patrick and John
Lindstrom noticed that their rabbits devel-
oped a flaccid paralysis and abnormal
electromyograms. These symptoms and
signs were dramatically ameliorated by
acetylcholinesterase inhibitors, charac-
teristic of human myasthenia gravis.
Steve and colleagues took the next
step and demonstrated that human9, October 9, 2014 ª2014 Elsevier Inc. 231
myasthenic sera reduced acetylcholine
sensitivity of human muscle cells in tissue
culture. This demonstration and develop-
ment of an animal model for myasthenia
gravis facilitated further translational
research into the disease and the conclu-
sion that human myasthenia gravis was
similarly an autoimmune disease of the
neuromuscular junction with autoanti-
bodies blocking acetylcholine receptor
function.
Between 1982 and 1991, Steve and
colleagues were the first to clone and
characterize subunits of the neuronal
nicotinic (nAChR) and glutamatergic re-
ceptor families. In 1991, Shigetada Naka-
nishi (in Japan) and his colleagues cloned
and characterized the first subunit of the
N-methyl-D-aspartate (NMDA) glutamate
receptor subtype, complementing these
studies. Characterization in the Heine-
mann Lab of cytisine as a partial agonist
of the a4/b2 nAChR that ostensibly medi-
ates the addictive properties of nicotine
was the impetus for the synthesis of vare-
nicline (Chantix), which is prescribed for
nicotine addiction and smoking cessa-
tion. With their molecular expertise, Steve
Heinemann’s group and Peter Seeburg’s
group (in Germany) independently char-
acterized not only a number of glutamate
receptor subunits but also RNA editing
of specific subunits (e.g., GluA2), which
accounted for their permeability to cal-
cium and hence their role in both neuro-
plasticity and neurodegeneration. These
findings have possible implications for
both global cerebral ischemia and amyo-
trophic lateral sclerosis. In 1989, Steve
was joined at the Salk Institute by one of232 Cell 159, October 9, 2014 ª2014 Elsevieus, Chuck Stevens, who moved from
Yale, and had a contiguous laboratory to
Steve’s.
More recently, Steve’s receptor dis-
coveries led to systems neurobiological
approaches with experiments using
gene knockouts to discern the impor-
tance of these receptors in neural
networks and behavior. Additional
studies with colleagues showed that
aberrant activation of both nicotinic
acetylcholine and glutamate receptors
in Alzheimer’s disease may mediate the
neurotoxic effect of b-amyloid peptide.
Specifically, b-amyloid engagement of
a7 nAChRs on astrocytes was found to
trigger astrocytic glutamate release. In
turn, glutamate activated extrasynaptic
NMDA-type glutamate receptors on
nearby neurons, stimulating a series of
deleterious molecular pathways that
contribute to synaptic damage, the un-
derlying defect accounting for memory
loss in Alzheimer’s. This work has pro-
vided the impetus to develop drugs for
Alzheimer’s disease using these recep-
tors as targets.
During his lifetime, Steve received
numerous awards and honors and was a
member of the National Academy of Sci-
ences, the Institute of Medicine, and the
American Academy of Arts and Sciences.
Steve was elected President of the Soci-
ety for Neuroscience and served that
organization faithfully, meeting tirelessly
with congressmen and others to advance
the cause of neuroscientists and increase
their level of funding.
Steve’s awards include the Bristol-
Myers Squibb Distinguished Achieve-r Inc.ment in Neuroscience Research Award,
the McKnight Award for Research, and
in 2010, the Julius Axelrod Prize for
exceptional achievements in neurophar-
macology and mentoring young scien-
tists. Along these lines, when he passed,
there was an outpouring of emails from
former students and postdoctoral fellows
praising his compassion and mentoring
skills.
In addition to his wife, Ann, Steve is sur-
vived by their five children, his four sisters,
and twelve grandchildren, all of whom
gave him great joy, especially when they
visited the family farm in Vermont during
the summers.
Finally, and perhaps most importantly,
we come to Steve Heinemann’s char-
acter. Steve had the best moral compass
of anyone, scientist or layperson, we have
ever known. He had the courage not only
to tell a good story but one that always
took the correct ethical stand no matter
what the consequences to him person-
ally. He was resolute in standing up for
the right course of action. He believed in
sharing scientific reagents such as the re-
ceptor clones generated in his laboratory
with other scientists shortly after their
publication and felt other scientists
should do likewise. Steve was a voice of
reason; he felt that scientific principles
and fairness of action, not politics, should
pave the pathway forward for scientific
endeavors. Whether you agreed or dis-
agreed with him, one has to respect the
values, achievements, humility, and hu-
manity of Steve Heinemann. Quite a
man, and on that final note, we can all
agree.Stuart A. Lipton1,2,*
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